Ionis Publishes 2023 Corporate Responsibility Report
Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a steady cadence of important new medicines to people with serious diseases
- Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a steady cadence of important new medicines to people with serious diseases
CARLSBAD, Calif., April 25, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future . - The report details Ionis' relentless passion to create better futures for people touched by serious disease as well as other stakeholders.
- In 2023, Ionis extended its commitment to corporate responsibility (CR) through the establishment of three strategic pillars with actionable goals.
- For more information on the 2023 Corporate Responsibility program, please visit: https://www.ionispharma.com/about/corporate-responsibility/
For more information about QALSODY, visit https://www.qalsody.com/ .